SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

ARS Pharmaceuticals faces a federal securities class action alleging it misled investors about the timing of expanded CVS Caremark insurance coverage for its neffy product. After ARS disclosed on June 24 that no new commercial formulary decisions would occur in the July 1 cycle and that CVS Caremark deferred its decision until January 2027, SPRY fell $2.52, or 23.9%, to $8.02 on June 25. Investors who bought shares between March 9 and June 24, 2026 have until October 5 to seek lead-plaintiff status.

Analysis

This is not new operating information; it is plaintiff-firm solicitation following an already disclosed reimbursement-timing setback. The near-term legal headline should have limited incremental fundamental impact on SPRY, but it reinforces that the market will discount management’s payer-access communications until the January formulary decision. For a commercial-stage single-product biotech, delayed broad coverage can produce a nonlinear revenue shortfall: lower prescription conversion reduces pharmacy stocking incentives and makes the sales-force cost base materially less efficient.

The relevant 1-3 month catalyst path is prescription-trend visibility, cash burn, and any revised 2027 revenue framework—not the October litigation deadline. Litigation expense and potential settlement are likely immaterial relative to the commercial-access question unless discovery establishes a broader pattern of disclosure failures; the greater risk is multiple compression from diminished management credibility and a need to fund commercialization before payer uptake improves. CVS has negligible direct earnings exposure, but the episode highlights PBM leverage over emerging drug launches and is directionally favorable to scaled manufacturers with established rebate infrastructure.

Contrarian view: the June repricing may have already capitalized much of a six-month delay if January coverage is secured and prescription demand proves resilient among cash-pay or covered patients. However, a long thesis requires independent evidence that demand is constrained by access rather than weak physician/patient adoption; absent weekly prescription data, formulary status by plan, and net-price disclosure, this is a watch item rather than a directional recommendation. A further cut to 2027 sales expectations, rising gross-to-net deductions, or a cash runway falling below 12 months would falsify any rebound case.

Key Decisions for Investors

• No new SPRY short solely on the litigation notice; the information is largely backward-looking and post-gap borrow/option-implied volatility may make a fresh short unattractive.
• Maintain an underweight or hedge existing SPRY exposure through the January 2027 CVS Caremark decision. Reassess after the next earnings release using prescription growth, net revenue per prescription, gross-to-net guidance, and cash runway as gating metrics.
• Set an event-driven alert for a favorable January formulary decision: if accompanied by unchanged cash-burn guidance and accelerating prescriptions, consider a tactical SPRY long for a 1-3 month credibility rerating. Exit if management again defers access timing or reduces its 2027 commercial outlook.
• Do not express the view through CVS; its exposure to one formulary decision is immaterial. The cleaner portfolio action is reducing binary commercial-stage biotech exposure where payer access—not clinical differentiation—is the principal near-term value driver.